Vitamin c may cut anemia drug needs in kidney patients
NCT ID NCT07076108
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether taking vitamin C by mouth can safely lower the amount of erythropoietin (a drug for anemia) needed by people with end-stage kidney disease on regular dialysis. Sixty adults on stable dialysis with low iron levels and moderate anemia took part. Researchers measured their hemoglobin, iron levels, and erythropoietin dose changes over three months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ain Shams University
Cairo, 11591, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access
- Pumpkin seed oil may fight inflammation in kidney patients — a trial puts it to the test